Antibacterial Drugs today: II.
Since the development of the sulphonamides in the 1930s and the subsequent development of antibiotics from the 1940s onwards, there have now been many drugs developed which are capable of chemotherapeutic activity in a patient infected by a susceptible micro-organism. This review is concerned with precise descriptions of important groups of antimicrobial drugs, with emphasis being placed on the more recently developed drugs. With each group of drugs the pharmacology, major therapeutic indications, dosages and adverse reactions are discussed. Part II of the review discusses the cephalosporins, polymyxins and aminoglycosides. The place of each in therapy is defined.
D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents; D002506:Cephalexin / Q000627:therapeutic use; D002509:Cephaloridine / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D002513:Cephamycins / Q000627:therapeutic use; D002515:Cephradine / Q000627:therapeutic use; D005601:Framycetin / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D010303:Paromomycin / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014031:Tobramycin / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D005839:Gentamicins; D011113:Polymyxins; D005601:Framycetin; D007612:Kanamycin; D010303:Paromomycin; D002515:Cephradine; D009355:Neomycin; D002509:Cephaloridine; D002506:Cephalexin; D002512:Cephalothin; D014031:Tobramycin; D013307:Streptomycin